Q2 EPS Forecast for Y-mAbs Therapeutics Reduced by Analyst
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) – Equities researchers at Wedbush lowered their Q2 2025 earnings per share estimates for Y-mAbs Therapeutics in a research report issued on Tuesday, May 13th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.29) per share for the quarter, down from their prior […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) – Equities researchers at Wedbush lowered their Q2 2025 earnings per share estimates for Y-mAbs Therapeutics in a research report issued on Tuesday, May 13th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.29) per share for the quarter, down from their prior […]
